CT findings in biomass smoke-associated interstitial lung disease: A retrospective analysis.

IF 1.1 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal of Clinical Imaging Science Pub Date : 2026-04-28 eCollection Date: 2026-01-01 DOI:10.25259/JCIS_225_2025
Jesse Gordon Bendetson, Helen Tran, Mina Sophia Kamangar, Keren Fogelfeld, Cecilia Matilda Jude, Nader Kamangar
{"title":"CT findings in biomass smoke-associated interstitial lung disease: A retrospective analysis.","authors":"Jesse Gordon Bendetson, Helen Tran, Mina Sophia Kamangar, Keren Fogelfeld, Cecilia Matilda Jude, Nader Kamangar","doi":"10.25259/JCIS_225_2025","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Household air pollution from biomass fuel combustion remains a major global health burden, affecting nearly 3 billion people worldwide. Although biomass smoke exposure is a recognized risk factor for chronic airway disease, its role in interstitial lung disease (ILD) is less well defined, and characteristic CT features have not been systematically described in patients without coexisting chronic obstructive pulmonary disease (COPD).</p><p><strong>Material and methods: </strong>We conducted a retrospective review of 23 patients with biomass smoke exposure and radiographic evidence of ILD, excluding those with alternative ILD etiologies or pre-existing COPD. CT scans were independently assessed by a thoracic radiologist and two pulmonologists for predominant patterns, distributions, and additional findings, with consensus classification. We report proportions with 95% confidence intervals (CIs) and performed exploratory Spearman correlation to assess associations between selected CT features.</p><p><strong>Results: </strong>The cohort (mean age 71.7 years; all females; 96% born outside the United States) most commonly demonstrated reticulation (16/23, 70%; 95% CI, 49-84%), ground-glass opacities (GGO) (15/23, 65%; 95% CI, 45-81%), mosaic attenuation (15/23, 65%; 95% CI, 45-81%), and bronchial wall thickening (14/23, 61%; 95% CI, 41-78%). Abnormalities were typically patchy (18/23, 78%; 95% CI, 58-90%) and peribronchial (13/23, 57%; 95% CI, 37-74%), without consistent apical or basal predominance. Traction bronchiectasis occurred in 12/23 (52%; 95% CI, 33-71%) and lymphadenopathy in 9/23 (39%; 95% CI, 22-59%). Honeycombing (5/23, 22%; 95% CI, 10-42%), centrilobular emphysema (4/23, 17%; 95% CI, 7-37%), nodules (3/23, 13%; 95% CI, 5-32%), cysts (2/23, 9%; 95% CI, 2-27%), tree-in-bud opacities (2/23, 9%; 95% CI, 2-27%), and centrilobular nodularity (1/23, 4%; 95% CI, 1-21%) were uncommon. Exploratory Spearman analyses showed strong associations between mosaic attenuation and bronchial wall thickening (ρ = 0.91) and between peribronchial distribution and mosaic attenuation (ρ = 0.83), with additional positive correlations between mosaic attenuation and bronchiectasis (ρ = 0.70), peribronchial distribution and bronchial wall thickening (ρ = 0.73), bronchial wall thickening and bronchiectasis (ρ = 0.77), bronchiectasis and traction bronchiectasis (ρ = 0.57), and reticulation and traction bronchiectasis (ρ = 0.69). Exploratory Spearman correlation analyses showed strong associations between mosaic attenuation and bronchial wall thickening (ρ = 0.91) and between peribronchial distribution and mosaic attenuation (ρ = 0.83), with additional positive correlations between mosaic attenuation and bronchiectasis (ρ = 0.70), peribronchial distribution and bronchial wall thickening (ρ = 0.73), bronchial wall thickening and bronchiectasis (ρ = 0.77), bronchiectasis and traction bronchiectasis (ρ = 0.57), and reticulation and traction bronchiectasis (ρ = 0.69).</p><p><strong>Conclusion: </strong>Biomass smoke-associated ILD demonstrates a distinctive CT pattern characterized by reticulation, GGOs, and mosaic attenuation with patchy and peribronchial distribution and no clear zonal predominance. Unlike hypersensitivity pneumonitis, it lacks centrilobular nodularity. Compared with idiopathic pulmonary fibrosis (IPF), it shows less extensive subpleural honeycombing, more peribronchial involvement, and no consistent basal predominance. These distinctions may improve recognition of biomass smoke-associated ILD in exposed patients. Further prospective studies are needed to validate these findings and clarify their prognostic significance.</p>","PeriodicalId":15512,"journal":{"name":"Journal of Clinical Imaging Science","volume":"16 ","pages":"17"},"PeriodicalIF":1.1000,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157916/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Imaging Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/JCIS_225_2025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Household air pollution from biomass fuel combustion remains a major global health burden, affecting nearly 3 billion people worldwide. Although biomass smoke exposure is a recognized risk factor for chronic airway disease, its role in interstitial lung disease (ILD) is less well defined, and characteristic CT features have not been systematically described in patients without coexisting chronic obstructive pulmonary disease (COPD).

Material and methods: We conducted a retrospective review of 23 patients with biomass smoke exposure and radiographic evidence of ILD, excluding those with alternative ILD etiologies or pre-existing COPD. CT scans were independently assessed by a thoracic radiologist and two pulmonologists for predominant patterns, distributions, and additional findings, with consensus classification. We report proportions with 95% confidence intervals (CIs) and performed exploratory Spearman correlation to assess associations between selected CT features.

Results: The cohort (mean age 71.7 years; all females; 96% born outside the United States) most commonly demonstrated reticulation (16/23, 70%; 95% CI, 49-84%), ground-glass opacities (GGO) (15/23, 65%; 95% CI, 45-81%), mosaic attenuation (15/23, 65%; 95% CI, 45-81%), and bronchial wall thickening (14/23, 61%; 95% CI, 41-78%). Abnormalities were typically patchy (18/23, 78%; 95% CI, 58-90%) and peribronchial (13/23, 57%; 95% CI, 37-74%), without consistent apical or basal predominance. Traction bronchiectasis occurred in 12/23 (52%; 95% CI, 33-71%) and lymphadenopathy in 9/23 (39%; 95% CI, 22-59%). Honeycombing (5/23, 22%; 95% CI, 10-42%), centrilobular emphysema (4/23, 17%; 95% CI, 7-37%), nodules (3/23, 13%; 95% CI, 5-32%), cysts (2/23, 9%; 95% CI, 2-27%), tree-in-bud opacities (2/23, 9%; 95% CI, 2-27%), and centrilobular nodularity (1/23, 4%; 95% CI, 1-21%) were uncommon. Exploratory Spearman analyses showed strong associations between mosaic attenuation and bronchial wall thickening (ρ = 0.91) and between peribronchial distribution and mosaic attenuation (ρ = 0.83), with additional positive correlations between mosaic attenuation and bronchiectasis (ρ = 0.70), peribronchial distribution and bronchial wall thickening (ρ = 0.73), bronchial wall thickening and bronchiectasis (ρ = 0.77), bronchiectasis and traction bronchiectasis (ρ = 0.57), and reticulation and traction bronchiectasis (ρ = 0.69). Exploratory Spearman correlation analyses showed strong associations between mosaic attenuation and bronchial wall thickening (ρ = 0.91) and between peribronchial distribution and mosaic attenuation (ρ = 0.83), with additional positive correlations between mosaic attenuation and bronchiectasis (ρ = 0.70), peribronchial distribution and bronchial wall thickening (ρ = 0.73), bronchial wall thickening and bronchiectasis (ρ = 0.77), bronchiectasis and traction bronchiectasis (ρ = 0.57), and reticulation and traction bronchiectasis (ρ = 0.69).

Conclusion: Biomass smoke-associated ILD demonstrates a distinctive CT pattern characterized by reticulation, GGOs, and mosaic attenuation with patchy and peribronchial distribution and no clear zonal predominance. Unlike hypersensitivity pneumonitis, it lacks centrilobular nodularity. Compared with idiopathic pulmonary fibrosis (IPF), it shows less extensive subpleural honeycombing, more peribronchial involvement, and no consistent basal predominance. These distinctions may improve recognition of biomass smoke-associated ILD in exposed patients. Further prospective studies are needed to validate these findings and clarify their prognostic significance.

生物质烟雾相关间质性肺疾病的CT表现:回顾性分析。
目标:生物质燃料燃烧造成的家庭空气污染仍然是全球主要的健康负担,影响到全世界近30亿人。虽然生物质烟雾暴露是慢性气道疾病的公认危险因素,但其在间质性肺疾病(ILD)中的作用尚不明确,并且未系统描述无慢性阻塞性肺疾病(COPD)患者的特征性CT特征。材料和方法:我们对23例有生物质烟雾暴露和ILD影像学证据的患者进行了回顾性研究,排除了其他ILD病因或已有COPD的患者。CT扫描由一名胸科放射科医生和两名肺科医生独立评估主要模式、分布和其他发现,并达成共识分类。我们报告了95%置信区间(ci)的比例,并进行了探索性的Spearman相关性来评估所选CT特征之间的关联。结果:该队列(平均年龄71.7岁,全部为女性,96%出生在美国以外)最常见的表现为网状(16/ 231,70 %;95% CI, 49-84%),毛玻璃混浊(15/ 232,65 %;95% CI, 45-81%),马赛克衰减(15/ 232,65 %;95% CI, 45-81%)和支气管壁增厚(14/ 231,61 %;95% CI, 41-78%)。异常通常为斑片状(18/ 23,78%;95% CI, 58-90%)和支气管周围(13/ 23,57%;95% CI, 37-74%),没有一致的根尖或基底优势。牵引性支气管扩张12/23 (52%,95% CI, 33-71%),淋巴结病变9/23 (39%,95% CI, 22-59%)。蜂窝状(5/ 23,22%;95% CI, 10-42%)、小叶中心肺气肿(4/ 23,17%;95% CI, 7-37%)、结节(3/ 23,13%;95% CI, 5-32%)、囊肿(2/ 23,9%;95% CI, 2-27%)、树状芽状混浊(2/ 23,9%;95% CI, 2-27%)和小叶中心结节(1/ 23,4%;95% CI, 1-21%)并不常见。探索性Spearman分析显示,马赛克衰减与支气管壁增厚(ρ = 0.91)、支气管周围分布与马赛克衰减之间有很强的相关性(ρ = 0.83),马赛克衰减与支气管扩张(ρ = 0.70)、支气管周围分布与支气管壁增厚(ρ = 0.73)、支气管壁增厚与支气管扩张(ρ = 0.77)、支气管扩张与牵拉性支气管扩张(ρ = 0.57)呈正相关。网状支气管扩张和牵引支气管扩张(ρ = 0.69)。探索性Spearman相关分析显示,马赛克衰减与支气管壁增厚(ρ = 0.91)、支气管周围分布与马赛克衰减(ρ = 0.83)之间存在很强的相关性,而马赛克衰减与支气管扩张(ρ = 0.70)、支气管周围分布与支气管壁增厚(ρ = 0.73)、支气管壁增厚与支气管扩张(ρ = 0.77)、支气管扩张与牵拉性支气管扩张(ρ = 0.57)之间存在正相关。网状支气管扩张和牵引支气管扩张(ρ = 0.69)。结论:生物质烟雾相关ILD具有独特的CT表现,以网状、GGOs和马赛克衰减为特征,呈斑片状和支气管周围分布,无明显的分区优势。与超敏性肺炎不同,它缺乏小叶中心结节性。与特发性肺纤维化(IPF)相比,它表现为较少的胸膜下蜂窝,更多的支气管周围累及,没有一致的基础优势。这些区别可以提高暴露患者对生物质烟雾相关ILD的认识。需要进一步的前瞻性研究来验证这些发现并阐明其预后意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Imaging Science
Journal of Clinical Imaging Science RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
2.00
自引率
0.00%
发文量
65
期刊介绍: The Journal of Clinical Imaging Science (JCIS) is an open access peer-reviewed journal committed to publishing high-quality articles in the field of Imaging Science. The journal aims to present Imaging Science and relevant clinical information in an understandable and useful format. The journal is owned and published by the Scientific Scholar. Audience Our audience includes Radiologists, Researchers, Clinicians, medical professionals and students. Review process JCIS has a highly rigorous peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts, affiliations and financial associations such that the published content is not biased.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书